ArticleCancer discovery2018
Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer.
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 44 citations in OpenAlex.
- CSF1R inhibitors mitigate CDK4/6 inhibitor-induced immunosuppression to increase antitumor immunity in HR+/HER2- breast cancer.Oncogene · 2026Article
- Systematic fusion transcript discovery in mantle cell lymphoma using long-read sequencing.bioRxiv : the preprint server for biology · 2026Article
- ESR1 fusions in breast cancer: functions, mechanisms and therapeutic opportunities.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Review
- Landscape of gene fusions in hormone receptor-positive breast cancer reveals ADK fusions as drivers of progression and potential therapeutic targets.Cell discovery · 2025Article
- Breast cancer: pathogenesis and treatments.Signal transduction and targeted therapy · 2025Review
- Targeted RNA Sequencing of Head and Neck Adenoid Cystic Carcinoma Reveals SEC16A::NOTCH1 Fusion and MET Exon 14 Skipping as Potentially Actionable Alterations.Head and neck pathology · 2024Article
- Estrogen Receptor Alpha Mutations, Truncations, Heterodimers, and Therapies.Endocrinology · 2024Review
- Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells.Breast cancer research and treatment · 2023Article
- Decoding Oncofusions: Unveiling Mechanisms, Clinical Impact, and Prospects for Personalized Cancer Therapies.Cancers · 2023Review
- The characteristics and clinical relevance of tumor fusion burden in non-EBV (+) gastric cancer with MSS.BMC gastroenterology · 2023Article
- Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series.The oncologist · 2023Article
- Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy.Molecular biomedicine · 2022Review
- Molecular characterization of ESR1 variants in breast cancer.Breast cancer research and treatment · 2022Article
- Locally advanced undifferentiated small round cell sarcoma of the lung with novel SDCCAG8-AKT3 fusion and type II tumor immunity in the microenvironment: a rare case report.Translational lung cancer research · 2022Article
- Fusion-associated carcinomas of the breast: Diagnostic, prognostic, and therapeutic significance.Genes, chromosomes & cancer · 2022Review
- ESR1 fusions and therapeutic resistance in metastatic breast cancer.Frontiers in oncology · 2022Review
- Gene Duplication and Gene Fusion Are Important Drivers of Tumourigenesis during Cancer Evolution.Genes · 2021Review
- Elucidation of Novel Therapeutic Targets for Breast Cancer withJournal of clinical medicine · 2021Article
- A Novel Neoplastic Fusion Transcript,Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Profiling Receptor Tyrosine Kinase Fusions in Chinese Breast Cancers.Frontiers in oncology · 2021Article
Corrections and comments
- Commented on by
Authors and funding
34 authors at 2 institutions in 1 country.
Karina J Matissek *Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
Maristela L Onozato *Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
Sheng Sun *Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
Zongli ZhengHarvard Medical School, Boston, Massachusetts.
Andrew SchultzMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Jesse LeeDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
Kristofer PatelMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Piiha-Lotta JerevallHarvard Medical School, Boston, Massachusetts.
Srinivas Vinod SaladiMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Allison MacleayDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
Mehrad TavallaiMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Tanja Badovinac-CrnjevicUniversity Hospital Zagreb, Zagreb, Croatia.
Carlos BarriosLatin America Cooperative Oncology Group (LACOG) and Pontificia Universidade Catolica do Rio Grande do Sul (PUCRS), Porto Alegre, Brazil.
Nuran BeşeDepartment of Radiation Oncology, Acibadem Breast Research Institute, Istanbul, Turkey.
Arlene ChanMount Hospital, Perth, Australia.
Yanin Chavarri-GuerraInstituto Nacional de Ciencias Medicas y Nutrición Salvador Zubiran, México City D.F., México.
Marcio DebiasiLatin America Cooperative Oncology Group (LACOG) and Pontificia Universidade Catolica do Rio Grande do Sul (PUCRS), Porto Alegre, Brazil.
Elif DemirdögenDepartments of Medical Biology, General Surgery, Pathology of Medical Faculty of Uludag University, Bursa, Turkey.
Ünal EgeliDepartments of Medical Biology, General Surgery, Pathology of Medical Faculty of Uludag University, Bursa, Turkey.
Sahsuvar GökgözDepartments of Medical Biology, General Surgery, Pathology of Medical Faculty of Uludag University, Bursa, Turkey.
Henry GomezInstituto Nacional de Enfermedades Neoplasicas, Lima, Perú.
Pedro LiedkeLatin America Cooperative Oncology Group (LACOG) and Pontificia Universidade Catolica do Rio Grande do Sul (PUCRS), Porto Alegre, Brazil.
Ismet TasdelenDepartments of Medical Biology, General Surgery, Pathology of Medical Faculty of Uludag University, Bursa, Turkey.
Sahsine TolunayDepartments of Medical Biology, General Surgery, Pathology of Medical Faculty of Uludag University, Bursa, Turkey.
Gustavo WerutskyLatin America Cooperative Oncology Group (LACOG) and Pontificia Universidade Catolica do Rio Grande do Sul (PUCRS), Porto Alegre, Brazil.
Jessica St LouisMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Nora HorickBiostatistics Center, Massachusetts General Hospital, Boston, Massachusetts.
Dianne M FinkelsteinHarvard Medical School, Boston, Massachusetts.
Long Phi LeHarvard Medical School, Boston, Massachusetts.
Aditya BardiaMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Paul E GossMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Dennis C SgroiHarvard Medical School, Boston, Massachusetts.
A John IafrateHarvard Medical School, Boston, Massachusetts.
Leif W EllisenMassachusetts General Hospital Cancer Center, Boston, Massachusetts. lellisen@mgh.harvard.edu.
Massachusetts General Hospital · USHarvard University · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
We sought to uncover genetic drivers of hormone receptor-positive (HR
Indexed as
Gene FusionAdultAgedAged, 80 and overAnimalsBreast NeoplasmsCell Line, TumorClass I Phosphatidylinositol 3-KinasesEstrogen Receptor alphaFemaleGene Expression Regulation, NeoplasticHeterocyclic Compounds, 3-RingHumansMice, NudeMiddle AgedProtein Kinase InhibitorsAKT3 protein, humanClass I Phosphatidylinositol 3-KinasesESR1 protein, humanEstrogen Receptor alphaHeterocyclic Compounds, 3-RingMK 2206PIK3CA protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-rafPyridonesPyrimidinonesRaf1 protein, humanReceptors, SteroidRibosomal Protein S6 KinasesRPS6KC1 protein, humantrametinib
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.